BMS Bolsters China Compliance In Wake Of SEC Fine
This article was originally published in PharmAsia News
Following an investigation under the US Foreign Corrupt Practices Act violations, Bristol-Myers Squibb has been fined for improper business activities in China, which has been strengthening policies on drug price monitoring and to control kickbacks to doctors. The US firm says the matter has been resolved through a number of steps to improve practices and compliance.
Register for our free email digests: